ATS 2024 Final Program

Click on the session title to view the speakers

40

SUNDAY • MAYs 19

P366 West Nile Encephalitis: A Case of Severe Encephalitis Causing Flaccid Paralysis and Guillain-Barre Like Syndrome P367 Where Are the Antibodies? A Case of Prolonged COVID19 Infection in an Immunocompromised Patient Status Post Rituximab Therapy P368 A Drug Reaction Waking Up a Virus P369 Unmasking of Connective Tissue- Interstitial Lung Disease (ILD) Following COVID-19 Infection P370 Two Cases of Slowly-Progressive Anti-MDA-5 ILD Post COVID-19 Infection P371 Shot and Clot: With a Genetic Twist Unveiled P372 A Rare Case of Candida Pneumonia in a Patient With Presumed Idiopathic CD4 Lymphopenia P373 Opening the Pandora’s Box: Unveiling Severe Immune Dysregulation and Coinfections in an HIV-positive Male P374 High-Risk Pulmonary Embolism and Acquired Protein C and S Deficiency in a Person With HIV/AIDS P375 Iris Associated HLH: Determining Appropriate Treatment Based on Underlying Etiology P376 Fluconazole Associated DRESS Syndrome in Patient With Coccidioidomycosis Pneumonia P377 Lamotrigine Induced Drug Reaction With Eosinophilia With Systemic Symptoms (DRESS)With HHV-6 Reactivation Causing Severe Encephalitis and Status Epilepticus P378 A Luminating Reaction: Anaphylactic Shock Following Lumason Administration P379 Nystatin Induced Laryngeal Edema - First Reported Case P380 Amlodipine: Not an Ace in the Hole P381 Indomethacin-induced Angioedema: A Rare and Challenging Case P382 A Case Report of Statin-induced Necrotizing Autoimmune Myopathy With Extramuscular Involvement P383 Hydroxychloroquine Induced Hypoglycemia P384 An Intriguing Case of Isolated Acute Severe Neutropenia Resistant to G-CSFS (Filgrastim) Can Cefazolin Be a Cause

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

A34 LATE BREAKING ABSTRACTS IN ASTHMA AND ALLERGIC INFLAMMATION 9:15 a.m. - 4:15 p.m. Viewing: Posters will be on display for entire session Discussion: 11:30-12:30 Discussionwith facilitators, authors, andattendees 12:30-1:15 Authorswill beby their posters for individual discussionwithattendees P386 A Comparative Analysis of Angiotensin-Converting Enzyme (ACE) Inhibitor-Induced Angioedema Versus Other Causes to Assess the Overall Burden P387 The Nigerian Asthma Registry: Initial Insights and Emerging Trends P388 Evaluation of Clinical Remission Indicators in Asthma Patients Treated With Biologics in a Real-world Setting P389 De Novo Asthma in Post COVID-19 Patients in Lima, Peru P390 Plasma Pharmacometabolomics of Inhaled Corticosteroids-related Adrenal Suppression in Asthma P391 Safety of Mepolizumab With 7429 Patient-years of Exposure: Pooled Analysis From 4175 Patients in 32 Clinical Studies Across Multiple Indications P392 Hypertension in Asthma: Something to Pay Attention To? P393 Plasma and Pulmonary Lipidomic Analysis of Post-Tuberculosis Lung Disease: From TB Diagnosis to Microbiologic Cure P394 Breaking News: Latest Update on LQ036 - The First-in-Class Inhaled IL-4R a Single Domain Antibody P395 Relative Attenuation of Mannitol Challenge by Anti-IL5RA or Anti-IL4RA in Severe Uncontrolled Asthma P396 A First-In-Human Study of ARO-RAGE, A Novel Inhaled RNA-Interference Therapy for Asthma San Diego Convention Center Area D (Hall A-B2, Ground Level)

ATS 2024 Conference Program • San Diego, CA